Fig. 1From: Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literatureFDG-PET and Clinical Response. FDG-PET maximum intensity projection in July 2018, prior to pembrolizumab treatment (top left panel) and in April 2019, over 6 months after her fourth and final pembrolizumab treatment (top right), with corresponding clinical photography of the patient's left shin from these time points (bottom left and bottom right respectively). In 2018, lesions over left shin were erythematous non-tender papules and nodules, with biopsy confirming metastatic melanomaBack to article page